Lycopene is a carotenoid found in multiple vegetables and fruits, 52 such as tomato and tomato-based products, papaya, and watermelon 53 [1] . Its beneficial health effects have been studied extensively, especially 54 in the prevention of prostate cancer where it has been demonstrated to 55 be a potential chemoprotective agent [2, 3] . Several studies suggest that 56 lycopene has an impact on adipose tissue metabolism. First, lycopene is 57 the predominant carotenoid in human adipose tissue [4] . Second, it has 58 recently been reported that a higher intake of lycopene was associated 59 with a smaller waist circumference and lower visceral and subcutane-60 ous fat mass [5] . Third, we demonstrated that lycopene inhibited proin-61 flammatory cytokine and chemokine expression in adipose tissue [6] .
62
Finally, it has been firmly established that the concentration of lycopene 63 in adipose tissue is correlated to a reduction in the risk of developing a 64 cardiovascular disease in men [7] . Such beneficial effects of lycopene
mice, lycopene can be metabolized by β-carotene 9',10'-dioxygenase 77 (BCDO2) [10, 11] . This enzyme is responsible for the eccentric cleavage 78 of lycopene (especially the cis-lycopene isomers). Indeed, Hu et al. 79 [10] demonstrated that the cis isomer of lycopene was metabolized 80 into apo-10'-lycopenal by ferret BCDO2 in vitro, and that all-trans lyco- identified in rat liver (apo-8'-lycopenal and apo-12'-lycopenal [12] ).
87
Apo-lycopenals were recently detected in human plasma, possibly 88 derived from ingested tomato products or from lycopene in vivo metab-89 olism [13] .
90
Among these metabolites, the apo-10-lycac has been shown to be an chial and lung cancer cells in vitro [15] . These data strongly suggest 99 that apo-10-lycac is highly active in terms of the regulation of gene 100 expression in organs that have an optimal environment for further 101 potential bioactivation to active metabolites.
102
Interestingly, BCDO2 is highly expressed in adipose tissue [16] .
103
Thus, we hypothesized that the apo-10-lycac and/or other related RAR. In the current study, we evaluated its effects on the transcrip- 
various concentration of apo-10-lycac or ATRA. ly [25] . For the detection of apo-10-lycac, we established a specific 3T3-L1 adipocytes were incubated with apo-10'-lycopenoic acid (2 μM) or ATRA (2 μM) for 24 h. RNA was extracted and hybridized on a whole mouse genome microarray. Data were computed using Genespring GX10. B. Filtered fold change (fold change of 1.5) of commonly regulated genes after treatment with ATRA (Y-axis) and apo-10'-lycopenoic acid (X-axis) were plotted. The correlation line was drawn, and the Pearson correlation coefficient and the associated P-value were calculated with SPSS 17. C. A heatmap was constructed for these filtered data using PermutMatrix. Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac.
Statistical analysis 242
Data are expressed as the means ± SEM. Significant differences 243 between control and treated groups were determined by one-way To study in detail the impact of apo-10-lycac (structure in Suppl. (119 were upregulated and 45 were downregulated (Fig. 1A) ), i.e.,
262
27% of the genes regulated by apo-10-lycac were also regulated by
263
ATRA, which suggests a selective overlap between the two genes lists.
264
In addition, the fold change of genes regulated by ATRA (Y-axis) was 265 plotted against the fold change of genes regulated by apo-10-lycac (X- 
271
It is noteworthy that genes previously shown to be modulated by
272
ATRA in adipocytes and/or adipose tissue ( pathways were significantly regulated by the two molecules (Table 2) .
277
Interestingly, of the pathways identified, the one called "Ligand- pathway, 21 were regulated by the treatments (P b 1.36e-04).
281
Taken together, these data suggested that apo-10-lycac and ATRA
282
shared similarities in terms of their effects on gene expression.
283
This was in agreement with the hypothesis of a similar action for 284 the same nuclear receptor. . Apo-10'-lycopenoic acid has no influence on 3T3-L1 adipocyte differentiation. At 2-days post-confluence, 3T3-L1 preadipocytes (day 0) were stimulated to induce differentiation with 0.5 mM isobutylmethylxanthine, 0.25 μM dexamethasone, and 1 μg/ml insulin, for 48 h. To examine the effect of apo-10'-lycopenoic acid on adipocyte differentiation, 2-days post-confluent 3T3-L1 preadipocytes received apo-10'-lycopenoic acid (2 μM) every 2 days or ATRA (2 μM) as a positive control until the end of the experiment at day 9. Total RNA was extracted and reverse transcribed with MMLV. Real time PCR was performed using specific primers. 18S rRNA was used as the endogenous control. Data are presented as means ± SEM; * represents a significant difference treated ATRA condition and control; P b 0.05. Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac. 
with apo-10-lycac and ATRA respectively. These effects were confirmed 314 in two additional models in the case of apo-10-lycac. Inguinal adipose tis-
315
sue explants of mice fed a high-fat diet were incubated ex vivo with apo-316 10-lycac (2 μM) for 24 h. We observed an important decrease of IL-6
317
(−58%) and IL-1β (−82%) mRNA levels in explants that were incubated 318 in the presence of apo-10-lycac compared to the control (Fig. 3A) . We also 319 used human primo cultures. Cells were incubated with apo-10-lycac 320 (2 μM) for 24 h, followed by incubation with TNFα (15 ng/ml) for 3 h. (1 μM).
338
In addition, we evaluated the induction of CYP26A1 and RARβ
339
( Fig. 4C) , two well-known RAR target genes in adipose tissue [34] .
340
Upon ATRA and apo-10-lycac treatment, these genes were strongly 
10-lycac, no peak that co-eluted with apo-10-lycac was observed. In ad- COOH-group [17] . As a reference we had apo-14'-lycopenoic acid with 391 six conjugated double bounds and an additional conjugated COOH-
392
group with an UVmax of 399 nm [17] . Thereby we postulated that 
Discussion

399
In the present study, we report for the first time the effects of apo- We used adipocytes as a model because they make up the main cellu- 
415
It is noteworthy that genes are more differentially affected by
416
ATRA than by apo-10-lycac, in terms of fold change in expression, as 417 reflected by the slope of the correlation line (Fig. 1B) . Such a discrep- A. 3T3-L1 adipocytes were incubated with apo-10'-lycopenoic acid (2 μM) or ATRA (2 μM) for 24 h and then incubated with TNFα (15 ng/ml) for 3 h. B. Adipose tissue of mice force fed with a high-fat diet for 6 weeks was recovered and incubated with apo-10'-lycopenoic acid (2 μM) for 24 h C. Human adipocytes were incubated with apo-10'-lycopenoic acid (2 μM) for 24 h and then incubated with TNFα (15 ng/ml) for 3 h. RNAs were extracted and reverse transcribed with MMLV. Real time RT-PCR was performed using specific primers. 18S rRNA was used as the endogenous control. Data are presented as means ± SEM; Bars not sharing the same letter were significantly different, P b 0.05. Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac.
shared with apo-10-lycac. Indeed, ATRA has been reported to impact A. Ten-to twelve-week-old RARE-luc mice, engineered to express firefly luciferase gene under the control of RARE, were treated with apo-10'-lycopenoic acid (4 mg/kg body weight; apo-10'-lycac), ATRA (50 mg/kg body weight) or DMSO by oral gavage 16 h before screening. Fifteen minutes after luciferin injection, white adipose tissue (WAT) and lungs were rapidly excised and placed in a tight light chamber for bioluminescence screening. Luciferase expression is expressed as integrated intensity/area. B. Mice were force fed apo-10'-lycopenoic acid (4 mg/kg body weight). Epididymal adipose tissue was recovered 16 h later. Total RNA was extracted and reverse transcribed using MMLV. Real time RT-PCR was performed using specific primers. 18S rRNA was used as the endogenous control. Means ± SEM are shown; values for 4-6 different animals per treatment group are shown. C. 3T3-L1 cells were transiently transfected with plasmids coding for Gal4-RAR and TKMH100x4-Luc. Cells were treated for 24 h with various concentrations of apo-10-lycac or ATRA. The β-galactosidase and luciferase dosages were performed as described in Materials and Method section. Bars not sharing the same letter were significantly different, P b 0.05.; Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac. Fig. 6 . Apo-10'-lycopenoic acid is not present in adipose tissue from mice treated with lycopene or apo-10'-lycopenoic acid as well as in human adipose tissue treated with lycopene, but a related compound dihydro-apo-10'-lycopenoic acid may be present. A. Male mice were treated intravenously with an aqueous lycopene-beadlet solution (50 mg/kg body weight). In vehicle treated animals, no peak was present and the data are not shown here. Using HPLC MS-MS with apo-10'-lycopenoic acid primed MRM settings we observed a peak in the spleen, which co-eluted with apo-10'-lycopenoic acid (marked by the scattered line), and small peaks, which co-eluted before and may correspond to potential geometric isomers of apo-10'-lycopenoic acid (marked by the scattered line box). In other tissues of lycopene-treated animals, such as serum, WAT, testis and liver, no co-eluting peak was observed. B. RARE-reporter mice with lycopene or apo-10'-lycopenoic acid treatment with up-regulated RARE activity and human adipocytes treated with/without lycopene were analyzed by HPLC MS-MS with apo-10'-lycopenoic acid primed MRM settings. C. RARE reporter mice with lycopene or apo-10'-lycopenoic acid treatment induced up-regulation of RARE activity were analyzed by HPLC MS-MS with SIR settings for 395 m/z. D. UV spectra of the peak with the MS of apo-10'-lycopenoic acid+ 2 Da (see Fig. 6C ). E. 7,8-dihydro-apo-10'-lycopenoic acid as a proposed chemical structure as an apo-10'-lycopenoic acid/lycopene-metabolite including a comparable structure of apo-14'-lycopenoic acid, a derivative with 6 conjugated double bounds. Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac, lycopene as LYC, and control as CTRL.
have a strong negative impact [42] [43] [44] experiments are required to demonstrate this in vivo.
486
We finally wanted to determine in this study whether apo-10-lycac or 487 related derivatives are present in tissues. 
